How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,297 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C

Shaare Zedek Medical Center Investigators Layout table for investigator information Principal Investigator: Bernardo Melamud, Dr. Gaucher Clinic , Shaare zedek Hospital More Information Go to Additional Information: Publications of Results: Zigmond E LG, Pappo O, Zangen S, Levy Sklair M, Hemed N, Rabbani E, Itamar R, Ilan Y, Margalit M. Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: A phase I/II clinical study. Hepatology 2006;44 .180A, . Other Publications: Layout table (...) Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2011 Clinical Trials

142. Choosing Wisely Canada recommendation - Don’t routinely do screening mammography for average risk women aged 40 – 49. Individual assessment of each woman’s preferences and risk should guide the discussion and decision regarding mammography screening in th

the Canadian Task Force on Preventive Health Care. Don’t do annual physical exams on asymptomatic adults with no significant risk factors. A periodic physical examination has tremendous benefits; it allows physicians to check on their healthy patients while they remain healthy. However, the benefits of this check-up being done on an annual basis are questionable since many chronic illnesses that benefit from early detection take longer than a year to develop. Preventive health checks should instead be done (...) at time intervals recommended by guidelines, such as those noted by the Canadian Task Force on the Periodic Health Examination. Don’t order DEXA (Dual-Energy X-ray Absorptiometry) screening for osteoporosis on low risk patients. While all patients aged 50 years and older should be evaluated for risk factors for osteoporosis using tools such as the osteoporosis self-assessment screening tool (OST), bone mineral density screening via DEXA is not warranted on women under 65 or men under 70 at low risk

2019 CPG Infobase

143. Risk reduction and management of delirium

have suggested it is geared more towards detection of hyperactive delirium, whereas hypoactive is more common in practice. 28-30 The CAM-ICU and Intensive Care Delirium Screening Checklist (ICDSC) have been developed and validated in ICU settings, and may be better suited than other tests for use in intensive care. 31 In all cases, a positive assessment should be followed by additional assessment and diagnosis against ICD-10 or DSM-5 criteria by a suitably trained clinician. 12,13 It is important (...) days. It is geared towards assessment of hyperactive delirium. Abbreviations: AMT – Abbreviated Mental Test; CAM – Confusion Assessment Method; DSD – delirium superimposed on dementia; DRS-98-R – Delirium Rating Scale; DOS - Delirium Observation Screening Scale; ICDSC – Intensive Care Delirium Screening Checklist; Nu-DESC – Nursing Delirium Screening Scale; MMSE – Mini Mental State Examination; RADAR – Recognising Acute Delirium As part of your Routine; mRASS – Modified Richmond Agitation-Sedation

2019 SIGN

144. British guideline on the management of asthma

is made. 9, 72 In adults, absence of smoking and young age of onset are typically included in algorithms designed to distinguish asthma from COPD. 12, 14, 15, 71, 72 3.3.1 Initial structured clinical assessment The predictive value of individual symptoms or signs is poor (see Table 1), and a structured clinical assessment including all information available from the history, examination and historical records should be undertaken. The clinical features that influence the probability that episodic (...) nature of the episodic symptoms. Wheeze confirmed by a healthcare professional on auscultation (see section 3.2.1) 22 It is important to distinguish wheezing from other respiratory noises, such as stridor or rattly breathing. Repeatedly normal examination of chest when symptomatic reduces the probability of asthma. Evidence of diurnal variability 18, 19, 22, 32, 73 Symptoms which are worse at night or in the early morning. Atopic history (see section 3.2.4) 17, 22, 62, 74, 76, 77 Personal history

2019 SIGN

145. Managing opioid use disorder in primary care: PEER simplified guideline

CFPlus.* Correspondence Dr Christina Korownyk; e-mail cpoag@ualberta.ca References 1. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (January 2016 to March 2018). Ottawa, ON: Public Health Agency of Canada; 2018. 2. Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of pre- scribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ (...) edition, criteria; however, the definition has changed over time. Given this inconsistent definition and differing study designs, a reasonable estimate of OUD risk after initial opioid prescription might be 4.7%, recognizing that stud- ies range broadly from 0% to 34%. 7-14 In response to the number of Canadians with OUD and the number of opioid- related deaths, the federal government launched a Canadian drugs and substances strategy. 15,16 In line with this strategy, national methadone prescribing

2019 CPG Infobase

146. Canadian guideline for Parkinson disease

. Copyright © 2019 Joule Inc. or its licensors 16 DIAGNOSIS AND PROGRESSION (M. Schlossmacher & E. Fon) Parkinson disease is characterized by a constellation of clinical manifestations, which include slowness of movement (brady- kinesia), rest tremor, rigidity and postural instability. Parkinson disease is a complex disorder that can be dicult to diagnose clinically, especially in the early stages when only some of its cardinal signs may be present. A diagnosis based on its etiology is impractical because (...) FOR PARKINSON DISEASE, 2ND ED PARKINSON DISEASE Parkinson-visual-9.pdf 1 2019-08-27 9:06 AM Parkinson-final-E.indd 4 2019-09-05 2:39 PMAppendix to: Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. CMAJ 2019. doi: 10.1503/cmaj.181504. Copyright © 2019 Joule Inc. or its licensors 5 COMMUNICATION n People with Parkinson disease should be encouraged to participate in choices about their own care. n Communication should be in verbal and written form. n Discussions should aim

2019 CPG Infobase

147. Corticosteroid therapy for sepsis

and mortality of hospital-treated sepsis. Current estimates and limitations . Rhodes A , Evans LE , Alhazzani W , et al . Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 . Shankar-Hari M , Phillips GS , Levy ML , et al. , Sepsis Definitions Task Force . Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3) . Franchimont D , Kino T , Galon J (...) trials and trial-level meta-analysis of the updated literature . Lamontagne F , Cohen D , Herridge M . Understanding patient-centredness: contrasting expert versus patient perspectives on vasopressor therapy for shock . Loisa P , Parviainen I , Tenhunen J , Hovilehto S , Ruokonen E . Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial . Briel M , Spoorenberg SMC , Snijders D , et al. , Ovidius Study Group , Capisce Study

2018 BMJ Rapid Recommendations

148. Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment

was made on the basis of incidence and relevance for the clinical picture. e: This includes general health status, physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning, each surveyed by means of the corresponding functional scale of the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30). AE: adverse event; CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organization for Research and Treatment of Cancer; MMST: Mini-Mental (...) ://www.dynamed.com/topics/dmp~AN~T116043/Glioblastoma. 3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl 5): v1-v49. 4. Weller M, Van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18(6

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

149. Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma

: Institute for Quality and Efficiency in Health Care Topic: Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T- cell non-Hodgkin lymphoma Commissioning agency: Federal Joint Committee Commission awarded on: 16 March 2019 Internal Commission No.: N17-02 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

150. Relationship between volume of services and quality of treatment outcome for stem cell transplantation

data), on the consideration of cluster effects (see Section 4.1.5), and on the examination of model quality [26]. The completeness of reporting (e.g. description of analysed data and reporting of point estimates, confidence intervals, and p-values) was considered an aspect of the informative value of results as well. On the basis of the entirety of these quality criteria, the observational studies were categorized by quality into those with high versus low informative value. 4.3.3 Assessment (...) in Health Care Topic: Relationship between volume of services and quality of treatment outcome for stem cell transplantations Commissioning agency: Federal Joint Committee Commission awarded on: 16 August 2018 Internal Commission No.: V18-02 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of rapid report V18-02 Version 1.0

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

151. Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V

of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A19-29 Version 1.0 Pembrolizumab (melanoma) 27 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Ingo Schmidt-Wolf, University Hospital Bonn, Germany IQWiG thanks the medical and scientific advisor for his (...) for Quality and Efficiency in Health Care (IQWiG) - v - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy AE adverse event AJCC American Joint Committee on Cancer BRAF BRAF: rapidly accelerated fibrosarcoma – isoform B CT CT: computed tomography CTCAE Common Terminology Criteria for Adverse Events CTLA-4 CTLA-4: cytotoxic T-lymphocyte-associated antigen 4 ECOG PS Eastern Cooperative Oncology Group Performance Status EMA European Medicines Agency EORTC QLQ-C30 European

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

152. Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V

according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 26 February 2019 Internal Commission No.: A19-23 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A19-23 Version 1.1 Rucaparib (ovarian cancer; maintenance treatment) 7 August 2019 Institute for Quality (...) 1.1 Rucaparib (ovarian cancer; maintenance treatment) 7 August 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy AE adverse event BRCA breast cancer associated gene CA-125 cancer antigen-125 CI confidence interval CT computed tomography CTCAE Common Terminology Criteria for Adverse Events DRS-P Disease-Related Symptoms Subscale – Physical ECOG PS Eastern Cooperative Oncology Group Performance Status

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

153. Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V

disorder in adults) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30 April 2019 Internal Commission No.: A19-40 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A19-40 Version 1.0 Lisdexamfetamine dimesylate (ADHD in adults) 30 (...) of lisdexamfetamine Research question Subindication ACT a Adults with ADHD with at least moderate severity since childhood b 1 Adults who have already received prior drug therapy Individual treatment involving the selection of atomoxetine and methylphenidate, in which the possible continuation or resumption with an already used drug must also be examined and presented, as part of a comprehensive treatment programme 2 Adults without prior drug treatment Atomoxetine or methylphenidate, as part of a comprehensive

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

154. Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report

Publisher: Institute for Quality and Efficiency in Health Care Topic: Data-supported timely management in cooperation with a physician-staffed centre for telemedicine in advanced cardiac failure Commissioning agency: Federal Joint Committee Commission awarded on: 29 March 2019 Internal Commission No.: N19-01 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de (...) failure, benefit assessment, systematic review Extract of rapid report N19-01 Version 1.0 Telemonitoring in advanced cardiac failure 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Table of contents Page List of tables iv List of figures v List of abbreviations vi Executive summary vii 1 Background 1 2 Research question 2 3 Course of the project 3 4 Methods 4 4.1 Criteria for the inclusion of studies in the investigation 4 4.1.1 Population 4 4.1.2 Experimental

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

155. Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults

below occurring within a 12-month period (American Psychiatric Association, 2013) . It is important to note that among older adults, some of these criteria may be modified by the aging process or their social roles (e .g ., retirement from work), resulting in more subtle presentations (Kuerbis et al ., 2014) . ? The BZRA is taken in larger amounts or over a longer period of time than intended . ? Persistent desire or unsuccessful efforts to cut down or control BZRA use . ? A great deal of time (...) Use Disorder ? 6 or more symptoms, severe BZRA Use Disorder Remission ? 3–12 months with no criteria other than craving is considered early remission . ? More than 12 months is considered sustained remission .6 Summary of Recommendations and Grades W e used the GRADE approach (Grading of Recommendations, Assessment, Development and Evaluation) as a method of grading the quality of evidence and the strength of recommendations . In following the GRADE process, the initial step was to grade

2019 CPG Infobase

156. Canadian guidelines on opioid use disorder among older adults

Disorder Among Older Adults Summary of Recommendations and Grades W e used the GRADE approach (Grading of Recommendations, Assessment, Development and Evaluation) as a method of grading the quality of evidence and the strength of recommendations . In following the GRADE process, the initial step was to grade the quality of available evidence supporting each recommendation . Subsequently, we identified the overall strength of the recommendation taking into account both the quality of the evidence (...) used a similar approach e .g . British Association for Psychopharmacology Guidelines (2012) . While such recommendations lack empirical evidence, we believe they are also useful and important . ***High quality evidence doesn’t necessarily imply strong recommendations, and strong recommendations can arise from low quality evidence. Note: Meta analyses and Randomized Controlled Trials are considered high quality vs. Observational studies which are considered low quality QUALITY OF EVIDENCE STRENGTH

2019 CPG Infobase

157. Negative pressure wound therapy for wounds healing by secondary intention

intention Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2017 Internal Commission No.: N17-01A Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of final report N17-01A Version 1.1 Negative pressure wound therapy – wounds healing by secondary intention 25 June 2019 Institute for Quality and Efficiency (...) The information retrieval identified 62 randomized controlled trials (119 documents) as relevant for the research question of this benefit assessment on NPWT in patients with wounds healing by secondary intention. Nine studies were only formally included because they fulfilled all inclusion criteria but failed to supply usable data on any outcome. Five additional studies reported usable data only on outcomes presented for supplementary information. For transparency purposes, these 14 studies were included

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

158. Negative pressure wound therapy for wounds healing by primary intention

Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2017 Internal Commission No.: N17-01B Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of final report N17-01B Version 1.0 Negative pressure wound therapy – wounds healing by primary intention 12 June 2019 Institute for Quality and Efficiency in Health Care (...) for bibliographic databases and trial registries are found in the appendix. The most recent search was conducted on 8 February 2019. Studies to be considered for N17-01B The information retrieval identified 54 randomized controlled trials (135 documents) as being relevant for the research question of this benefit assessment on NPWT in patients with wounds healing by primary intention. Six studies were included only formally because they fulfilled all inclusion criteria, but failed to supply usable data on any

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

159. Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of final report A16-70 Version 1.0 Biologics for rheumatoid arthritis 23 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - This report was prepared in collaboration with external experts. The responsibility for the contents of the report lies solely with IQWiG (...) components: number of painful joints, number of swollen joints, global assessment of disease activity by the patient, and global assessment of disease activity by the physician [16] ? Definition where all criteria must be met (designated as Boolean definition): = 1 painful joint, = 1 swollen joint, CRP = 1 mg/dl, and global assessment of disease activity by the patient = 1 on a scale of 0 to 10 Extract of final report A16-70 Version 1.0 Biologics for rheumatoid arthritis 23 July 2019 Institute

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

160. Children and young people exposed prenatally to alcohol

for the assessment and diagnosis of children and young people affected by PAE. It includes evidence-based recommendations on measurement of alcohol consumption in pregnancy and consensus-based recommendations on: y identification of children at risk of FASD y criteria for diagnosis and use of FASD as a descriptor y medical assessment y physical examination y sentinel features y neurodevelopmental assessment y the multidisciplinary assessment team y special considerations in the neurodevelopmental assessment y (...) The need for guidance 1 1.2 Remit of the document 3 1.3 Definitions and terminology 3 1.4 Origin of this guidance 8 1.5 Statement of intent 9 2 Identification of children at risk of FASD 10 2.1 Maternal alcohol history 10 3 Identification and assessment of children and young people affected by prenatal alcohol exposure 15 3.1 Diagnostic criteria 15 3.2 Medical assessment 17 3.3 Sentinel facial features 18 3.4 Neurodevelopmental assessment 19 3.5 Special considerations in the assessment of infants

2019 SIGN

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>